Nitric oxide inhibits chondrocyte response to IGF-I: inhibition of IGF-IRbeta tyrosine phosphorylation

Am J Physiol Cell Physiol. 2000 Oct;279(4):C961-9. doi: 10.1152/ajpcell.2000.279.4.C961.

Abstract

Chondrocytes in arthritic cartilage respond poorly to insulin-like growth factor I (IGF-I). Studies with inducible nitric oxide synthase (iNOS) knockout mice suggest that NO is responsible for part of the cartilage insensitivity to IGF-I. These studies characterize the relationship between NO and chondrocyte responses to IGF-I in vitro, and define a mechanism by which NO decreases IGF-I stimulation of chondrocyte proteoglycan synthesis. Lapine cartilage slices, chondrocytes, and cartilage from osteoarthritic (OA) human knees were exposed to NO from the donors S-nitroso-N-acetylpenicillamine (SNAP) or (Z)-1-[2-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1- ium-1, 2-diolate] (DETA NONOate), by transduction with adenoviral transfer of iNOS (Ad-iNOS), or by activation with interleukin-1 (IL-1). NO synthesis was estimated from medium nitrite, and proteoglycan synthesis was measured as incorporation of (35)SO(4). IGF-I receptor phosphorylation was evaluated with Western analysis. SNAP, DETA NONOate, endogenously synthesized NO in Ad-iNOS-transduced cells, or IL-1 activation decreased IGF-I-stimulated proteoglycan synthesis in cartilage and monolayer cultures of chondrocytes. OA cartilage responded poorly to IGF-I; however, the response to IGF-I was restored by culture with N(G)-monomethyl-L-arginine (L-NMA). IGF-I receptor phosphotyrosine was diminished in chondrocytes exposed to NO. These studies show that NO is responsible for part of arthritic cartilage/chondrocyte insensitivity to anabolic actions of IGF-I; inhibition of receptor autophosphorylation is potentially responsible for this effect.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Cartilage, Articular / cytology
  • Cartilage, Articular / drug effects
  • Cartilage, Articular / metabolism
  • Cells, Cultured
  • Chondrocytes / cytology
  • Chondrocytes / drug effects
  • Chondrocytes / metabolism*
  • Dose-Response Relationship, Drug
  • Humans
  • In Vitro Techniques
  • Insulin-Like Growth Factor I / metabolism*
  • Insulin-Like Growth Factor I / pharmacology
  • Interleukin-1 / pharmacology
  • Nitric Oxide / metabolism*
  • Nitric Oxide / pharmacology
  • Nitric Oxide Donors / pharmacology
  • Nitric Oxide Synthase / antagonists & inhibitors
  • Nitric Oxide Synthase / genetics
  • Nitric Oxide Synthase / metabolism
  • Nitric Oxide Synthase Type II
  • Nitrites / metabolism
  • Nitroso Compounds / pharmacology
  • Osteoarthritis / metabolism*
  • Osteoarthritis / pathology
  • Penicillamine / analogs & derivatives*
  • Penicillamine / pharmacology
  • Phosphorylation / drug effects
  • Proteoglycans / biosynthesis
  • Rabbits
  • Receptor, IGF Type 1 / metabolism*
  • S-Nitroso-N-Acetylpenicillamine
  • Tyrosine / metabolism
  • omega-N-Methylarginine / pharmacology

Substances

  • Interleukin-1
  • Nitric Oxide Donors
  • Nitrites
  • Nitroso Compounds
  • Proteoglycans
  • 2,2'-(hydroxynitrosohydrazono)bis-ethanamine
  • omega-N-Methylarginine
  • Nitric Oxide
  • Tyrosine
  • Insulin-Like Growth Factor I
  • S-Nitroso-N-Acetylpenicillamine
  • NOS2 protein, human
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type II
  • Receptor, IGF Type 1
  • Penicillamine